The ​Trump administration will end a subsidy ​program, meant to keep premiums stable for Medicare prescription ​drug plans, after 2026, the Centers for Medicare & Medicaid Services said on Tuesday.The agency said its review of 2027 bids showed insurers have gained enough experience with ‌Medicare Part ⁠D to ⁠accurately price their plans without support from the program."We are stabilizing the market so this bailout is no longer needed. Premiums will go up by less than $10 for most Medicare recipients, with many even seeing lower premiums," CMS Administrator Dr. Mehmet Oz said in a post on X.Medicare Part D, ​which provides prescription drug coverage to millions of ⁠beneficiaries through ‌private insurance plans, is a key component of the ​federal health ​program for older adults.Healthcare costs remain a concern ⁠for many older Americans on fixed incomes. Nearly 25 million ​people were enrolled in standalone Medicare Part D drug ​plans in 2026, according to KFF, a health policy research group.Major Medicare Part D insurers include UnitedHealth Group , Humana and CVS Health's Aetna.The Wall Street Journal first reported the development earlier in the day.The decision comes as the Trump administration pursues broader changes to ‌government health programs, including a proposal to overhaul Medicare physician payments and increase oversight of federal healthcare spending.CMS also released ​preliminary information ​on 2027 Medicare drug-plan ⁠bids. The national average monthly bid amount, a measure used to calculate government subsidies for plans, will be $296.05 in 2027.The agency said the national base ​beneficiary premium for Medicare Part D will be $41.33 next year. Annual increases in that premium remain capped at 6% through 2029 under provisions of the Inflation Reduction Act.CMS said it will release final 2027 Medicare Advantage and Part D premiums and plan details in September.